Key Takeaways Labcorp expanded its precision oncology portfolio with new solid tumor and hematologic cancer tests. LH added HRD testing and HER2 subtyping, and launched the Rapid AML Panel for advanced cancer profiling. Labcorp launched a global digital pathology platform to boost companion diagnostic development efforts.Labcorp (LH) recently announced the expansion of its precision oncology portfolio, which includes new test offerings for solid tumor and hematologic malignancies and enhanced biopharma so ...

New test offerings target solid tumors and hematologic malignanciesEnhanced biopharma services support accelerated clinical trials and companion diagnostic developmentBURLINGTON, N.C., May 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate ...